Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13071971 | 0.78 | ESR1 (0.34) | EPHX2NR1H4IDO1 | |
| SCHEMBL22868057 | 0.74 | PRSS1 (0.35) | EPHX2NR1H4IDO1 | |
| SCHEMBL18103219 | 0.71 | KMT2A (0.59) | EPHX2NR1H4 | |
| SCHEMBL7670360 | 0.68 | ESR1 (0.38) | IDO1 | |
| SCHEMBL22868058 | 0.66 | SRD5A2 (0.50) | EPHX2NR1H4 | |
| SCHEMBL22101643 | 0.66 | — | — | |
| SCHEMBL21020735 | 0.66 | THRA (0.34) | EPHX2NR1H4 | |
| SCHEMBL1505324 | 0.65 | ALDH1A1 (0.59) | — | |
| SCHEMBL10588426 | 0.65 | KMT2A (0.43) | — | |
| SCHEMBL18290661 | 0.65 | MAPT (0.48) | EPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200188430-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | OREGON STATE UNIVERSITY (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200188430-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | TUFM, SMN1; SMN2, MCU | NOS3 3691/4885NOS1 3391/4885NOS2 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.